Success story
Toronto's WinterLight Labs is working on novel AI technology that can diagnose and monitor cognitive diseases like dementia.
Biolab Farmacêutica, one of Brazil's largest pharmaceutical firms, opens its first international research and development centre in Ontario.
Spotlight
Toronto is the best kept secret in North America.
With its unique approach to detecting and responding to data threats, Ontario's eSentire Inc. has emerged as a leader in the $100-billion global cybersecurity market.
Site Selection Magazine names Ontario the best place in Canada for investment, while recognizing 11 top Ontario cities.
BlueRock Therapeutics, launched in 2016 with the second-largest series A financing in biotech history, aims to build a transformational regenerative medicine platform.
SecureKey in Toronto, Ontario offers innovative solutions that let consumers use their digital credentials with a trusted provider to access a host of online services.
CBRE Scoring Tech Talent 2017 rates Toronto as one of North America's most attractive cities.
InteraXon, a fast-rising biotech star with expertise in brain-sensing technology, has its roots in Ontario talent and mentorship—and its sights on the world.
Video
The launch of the Vector Institute in Toronto establishes Ontario as a top Artificial Intelligence R&D hub.
Renowned as a pioneer of modern artificial intelligence, Ontario's investment in the Vector Institute for Artificial Intelligence establishes the province as a world-leading AI research and development hub.
Artificial intelligence is reshaping the world we live in. Top experts from the University of Toronto weigh in on what an AI-enabled world may look like by 2050.
Discover how Ontario companies are impacting the market and the future of global industries through clean technologies.
To maintain market leadership and continually improve its services, PayCommerce decided to build a new R&D centre right here in Ontario.
Led by the Province of Ontario, Canadian venture capital activity in 2016 increased by 36% despite a global decline in funding.
Request a conversation
Sign up now
